BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced primary results from CheckMate -649, the pivotal Phase 3 trial in which first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in the overall survival (OS) and progression-free survival (PFS) of patients with unresectable advanced or metastatic gastric cancer,

Pathline Labs, a leading provider of sub-specialized anatomic pathology, has expanded its COVID-19 testing capabilities across the country while maintaining a 24-36-hour turnaround time for processing.

Bristol Myers Squibb (NYSE: BMY) today announced first results from the Phase 3 CheckMate -577 trial in which adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS), the trial’s primary endpoint,

The Medical Device Innovation Consortium (MDIC) today announced that its board of directors has elected Jijo James, Chief Medical Officer of Johnson & Johnson Medical Devices Companies, as the new chair-elect of the MDIC board.

- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA ® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed by Veterans Affairs Canada (VAC) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB)

The Centers for Disease Control and Prevention (CDC), which according to its website is “recognized as the nation’s premiere health promotion, prevention and preparedness agency,” is playing a leading role in response to the COVID-19 pandemic. In the fall issue of the Journal of American Physicians and Surgeons , editor-in-c

Patients suffering from chronic and acute pain disorders will benefit from a convenient, discreet, and easy-to-use device delivering a novel alternative to opioid-based pain management.

VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020. Presentation Details: Date: Wednesda

A new ad hoc analysis from the Phase III ARAMIS trial showed 97.2% of men with non-metastatic castration-resistant prostate cancer (nmCRPC) taking NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) received the full, planned dose of 600 mg twice daily compared to 98.4% who received ADT alone

Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Maybelle Jordan, Vice President of Business Development of Biomerix Corporation, and Brigid Makes, former Senior Vice President and Chief Financial Officer of Miramar Labs, have joined its board of directors. Maybell